# IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease

> **NCT00523159** · PHASE2 · COMPLETED · sponsor: **Immatics Biotechnologies GmbH** · enrollment: 68 (actual)

## Conditions studied

- Renal Cell Carcinoma

## Interventions

- **DRUG:** Endoxana, IMA901, Leukine
- **DRUG:** IMA901 and Leukine

## Key facts

- **NCT ID:** NCT00523159
- **Lead sponsor:** Immatics Biotechnologies GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00523159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00523159, "IMA901 in Advanced Renal Cell Carcinoma Patients With Measurable Disease". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00523159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*